«BioEq» team attended the 13th Congress of the European Association for clinical pharmacology and therapeutics (EACPT), which took place in Prague from 24 to 27 June. EACPT 2017 is major opportunity for clinical pharmacologists from Europe and all over the world to meet and discuss hot scientific topics of interest to the scientific community and society in general.
«BioEq» is a first dedicated clinical research unit for early and late stage trials. «BioEq» focuses on bioequivalence, therapeutic equivalence and phase I-IV studies.
Anna Galustyan, working at «BioEq» as the Principal Investigator represented our company at the 13th Congress of the European Association for clinical pharmacology and therapeutics (EACPT). During a poster session she presented results of a bioequivalence study of Metformin and Empaglyflosin with submission of results to EMA conducted at «BioEq».
To set up a meeting please contact us at bd@bioeq.ru
Looking forward to seeing you at the 13th Congress of the European Association for clinical pharmacology and therapeutics (EACPT)!